Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310514 | 0.81 | PDE3B (0.44) | KDRAURKAPDE3BPDE3A | |
| SCHEMBL3836082 | 0.70 | DUT (0.36) | KDRAURKA | |
| SCHEMBL25302444 | 0.69 | KDR (0.41) | CA12CA9KDRAURKA | |
| SCHEMBL30068982 | 0.69 | KDR (0.41) | CA12CA9KDRAURKA | |
| SCHEMBL23089173 | 0.67 | GRM5 (0.37) | CA12CA9KDRAURKA | |
| SCHEMBL5311516 | 0.67 | AURKA (0.37) | CA12CA9KDRAURKA | |
| SCHEMBL3837257 | 0.67 | PDE3B (0.43) | KDRAURKAPDE3BPDE3A | |
| SCHEMBL17318153 | 0.67 | CA12 (0.47) | PREPCA12CA1CA9 | |
| SCHEMBL23599361 | 0.67 | PREP (0.43) | PREPCA12CA1CA9 | |
| SCHEMBL30825366 | 0.67 | PIK3CD (0.37) | PREPCA12CA1CA9KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | PREP 3472/4885CA12 4863/4885CA1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.